Abstract 956P
Background
Microvascular invasion (MVI) is closely associated with high risk of recurrence and poor long-term survival in HCC patients. For these patients, active and effective adjuvant therapy is of great significance to improve the prognosis. Therefore, we explored the efficacy and safety of interferon-α (IFN-α) combined with PD-1 monoclonal antibody (tislelizumab, TIS) as adjuvant therapy for HCC patients with MVI.
Methods
In this phase 2 study, histologically confirmed HCC patients who had undergone curative resection with MVI, Child-Pugh A, and an ECOG PS ≤1 were enrolled. Patients separately received TIS (200 mg IV Q3W) plus IFN-α (30 μg BIW) or active surveillance until disease progression, intolerable toxicity or withdrawal of consent. The primary endpoint was recurrence free survival (RFS). Secondary endpoints included overall survival (OS) and safety.
Results
From January 2021 to December 2021, TIS plus IFN-α group and active surveillance group enrolled 24 and 14 patients, respectively. Baseline characteristics were generally comparable between two groups, including MVI grade (M1: 90.0% vs 85.7%; M2: 10.0% vs 14.3%) and any tumours diameter > 5cm (65.0% vs 50.0%) in TIS plus IFN-α, respectively. At data cutoff (17 Apr 2023), RFS was not reached in TIS plus IFN-α group (95%CI: 9.8-NE), whereas in active surveillance group was 17.09 month (95%CI: 4.8-NE). 1-year RFS rate in TIS plus IFN-α and active surveillance group was 79.2% (95%CI: 0.5-0.9) and 50.0% (95%CI: 0.2-0.7), separately. Median OS was not reached in either group. No severe postoperative complications were observed. In TIS plus IFN-α group, Grade 1 or higher AEs were mainly rash (20.0%), pyrexia (15.0%), pruritus (10.0%) and diarrhea (10.0%).
Conclusions
These results suggested that HCC patients with MVI may benefit from adjuvant tislelizumab plus IFN-α, which can be tested in a future confirmatory trial. We will continue follow-up and update the data further. In the meantime, related basic experiments are underway.
Clinical trial identification
ChiCTR2000037461.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Shanghai Shenkang Hospital Development Center (No. SHDC2020CR3031B).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18